Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 9,907 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single Arm Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Facebook and Friends: Developing an Effective Online Social Network for Weight Loss

NCT02656680
View directory record Official record
Conditions
Weight Loss
Interventions
Continuous Enrollment, Closed Enrollment
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 23, 2026, 9:45 AM EDT
Completed Phase 2 Interventional

Study of TNFerade™ Gene Therapy, Radiation, 5-FU and Cisplatin in Esophageal Cancer

NCT00051480
View directory record Official record
Conditions
Esophageal Cancer
Interventions
TNFerade
Genetic
Lead sponsor
GenVec
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
La Jolla, California • Orange, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Oct 23, 2026, 9:45 AM EDT
Not yet recruiting Phase 4 Interventional

Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

NCT07864480
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetes
Interventions
PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab
Device · Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 9:45 AM EDT
Withdrawn Phase 2 Interventional

A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy

NCT05178576
View directory record Official record
Conditions
Colon Cancer
Interventions
Gevokizumab, Signatera test
Drug · Diagnostic Test
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Gainesville, Florida • Iowa City, Iowa • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 23, 2026, 9:45 AM EDT
Recruiting Phase 4 Interventional

Menopausal HT for Women Living With HIV (HoT)

NCT06856174
View directory record Official record
Conditions
HIV Infection, Menopause
Interventions
Transdermal estradiol gel, Micronized Progesterone, Placebo for estradiol gel, Placebo for micronized progesterone
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
40 Years to 60 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 9:45 AM EDT
Terminated Not applicable Interventional

A Critical Illness Recovery Navigator for Alcohol

NCT03059082
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Recovery Navigator on an as needed basis up to 6 months, Recovery Navigator prior to hospital discharge, No interaction with Recovery Navigator
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 23, 2026, 9:45 AM EDT
Terminated Phase 1 Interventional

Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors

NCT00606879
View directory record Official record
Conditions
Advanced Cancer
Interventions
SGX523 Capsules
Drug
Lead sponsor
SGX Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Santa Monica, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 24, 2008 · Synced Oct 23, 2026, 9:45 AM EDT
Recruiting Not applicable Interventional

Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients

NCT06615635
View directory record Official record
Conditions
Squamous Cell Carcinoma, Alpha Radiation, Immunocompromised, Carcinoma, Squamous, Skin Cancer, Brachytherapy
Interventions
DaRT seeds
Device
Lead sponsor
Alpha Tau Medical LTD.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
10
States / cities
Gilbert, Arizona • Phoenix, Arizona • Boca Raton, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS

NCT05323708
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bmab 1000, Prolia®
Biological
Lead sponsor
Biocon Biologics UK Ltd
Industry
Eligibility
28 Years to 55 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 23, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Results available

Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop

NCT02328040
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo and Insulin monotherapy via CL, Sitagliptin and insulin/novolog via CL
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
14 Years to 30 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 23, 2026, 9:45 AM EDT
Terminated Phase 1 Interventional

AHN-12 Biodistribution in Advanced Leukemia

NCT01207076
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
Interventions
90Y-AHN-12
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 23, 2026, 9:45 AM EDT
Terminated Phase 2 Interventional

Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer

NCT00521274
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
MVA 5T4, Docetaxel
Biological · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 23, 2026, 9:45 AM EDT
Completed Not applicable Interventional Results available

Use of Joystick-operated Ride-on-toys to Improve Affected Arm Use and Function in Children With Hemiplegic Cerebral Palsy

NCT05559320
View directory record Official record
Conditions
Hemiplegic Cerebral Palsy
Interventions
Ride-on-toy navigation training, Upper extremity functional training
Device · Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
3 Years to 8 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 23, 2026, 9:45 AM EDT
Active, not recruiting Not applicable Interventional

Mirror Speech Entrainment: A Novel Technique for Voice Personalized Speech Entrainment for Nonfluent Aphasia

NCT06829420
View directory record Official record
Conditions
Aphasia Non Fluent, Stroke, Aphasia
Interventions
Mirror speech entrainment, Traditional speech entrainment: auditory-only, Traditional speech entrainment: auditory-visual
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 9:45 AM EDT
Terminated Phase 1 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

NCT03465540
View directory record Official record
Conditions
Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, AML, MDS, NHL
Interventions
AMG 397, Dexamethasone, Azacitidine
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 23, 2026, 9:45 AM EDT
Active, not recruiting Phase 3 Interventional

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

NCT05881408
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
delandistrogene moxeparvovec, placebo
Genetic
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
Male only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 9:45 AM EDT
Completed Phase 2 Interventional

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

NCT03113825
View directory record Official record
Conditions
Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer
Interventions
Investigational Imaging device, AVB-620
Device · Drug
Lead sponsor
Avelas Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
San Diego, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 23, 2026, 9:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparing Modes of Telehealth Delivery: Phone vs. Video Visits (ASSIST)

NCT04616118
View directory record Official record
Conditions
Rheumatic Disease, Cardiac Disease, Primary Care, Infectious Disease
Interventions
Phone Visit, Video Visit
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 23, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)

NCT00424710
View directory record Official record
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
ranibizumab intravitreal injection
Drug
Lead sponsor
Hawaii Pacific Health
Other
Eligibility
25 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Honolulu, Hawaii • ‘Aiea, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 23, 2026, 9:45 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer

NCT01334710
View directory record Official record
Conditions
Liver Cancer
Interventions
Sorafenib and OSI-906
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 23, 2026, 9:45 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

NCT07213960
View directory record Official record
Conditions
FSGS
Interventions
APL2, Placebo
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 23, 2026, 9:45 AM EDT
Withdrawn Not applicable Interventional

Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma

NCT02540135
View directory record Official record
Conditions
High Grade Malignant Neoplasm, Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
fluorescein, intraoperative MRI
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 23, 2026, 9:45 AM EDT
Completed Not applicable Interventional

Ayurveda Diet & Lifestyle Protocol for Type 2 Diabetes: A Feasibility Study

NCT07400276
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Maharishi Ayurveda Lifestyle Program
Behavioral
Lead sponsor
Maharishi International University
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 23, 2026, 9:45 AM EDT
Completed Not applicable Interventional

Investigating the Feasibility and Implementation of Whole Genome Sequencing in Patients With Suspected Genetic Disorder

NCT03829176
View directory record Official record
Conditions
Hereditary Disease, Genetic Predisposition to Disease
Interventions
Whole Genome Sequencing
Genetic
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
3 Months and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 23, 2026, 9:45 AM EDT